Stop Picking Sites Blind: The Real Peak Performance Fix for Faster Enrollment

Every clinical trial sponsor knows the pain: you pick a site that looks perfect on paper—strong PI, experienced coordinator, solid patient database—and then enrollment crawls. Six months later you are scrambling to add backup sites while the timeline slips. The root cause is almost always the same: picking sites based on incomplete signals while ignoring systematic feasibility criteria. This guide offers a structured fix that teams can adopt immediately, grounded in common industry practices as of May 2026.

We will walk through why traditional site selection fails, present a balanced framework that blends quantitative and qualitative factors, and give you a repeatable process to evaluate sites before contracts are signed. No invented studies, no magic formulas—just practical trade-offs and decision rules that experienced operations teams use.

Why Picking Sites Blind Costs You Enrollment Speed

Most site selection today still relies on a shortlist built from previous trial performance, investigator reputation, or a quick feasibility survey. While those inputs are not useless, they miss three critical dimensions: patient population density, site capacity at the time of startup, and the real-world logistics of recruitment.

The Hidden Gaps in Common Selection Criteria

Past performance is a noisy signal. A site that enrolled fast in a diabetes trial may struggle in a rare disease study because the patient pool is different. Investigator enthusiasm often fades once the contract arrives and the coordinator workload is revealed. Feasibility surveys tend to be optimistic—sites overestimate their patient counts and underestimate their competing trials.

Teams that skip a structured feasibility assessment routinely discover only after activation that the site has three other studies competing for the same patients, or that the catchment area has far fewer eligible patients than anticipated. One composite scenario: a high-profile academic site promised 15 patients per month for a Phase 3 neurology trial; after six months they had enrolled three. A post-mortem showed they had not checked their own electronic health records for diagnosis codes before signing the contract.

Another common blind spot is coordinator bandwidth. Even a star investigator cannot enroll if the study coordinator is stretched across five trials. Many organizations do not verify current workload during selection, assuming the site will hire staff. In practice, hiring delays can push first-patient-in by three to six months.

The Cost of Correcting Bad Selections

When a site underperforms, the sponsor either adds replacement sites—which extends startup timelines and increases monitoring costs—or extends the enrollment period, which delays database lock and regulatory submission. Industry surveys suggest that replacing a site mid-trial can add 20–30% to the per-patient cost for that site, not counting the opportunity cost of delayed market entry. A data-driven upfront selection is the cheapest insurance against those overruns.

Core Frameworks: What Drives Faster Enrollment

Enrollment speed is not random. It follows predictable patterns when you align site selection with three core drivers: patient access, site readiness, and protocol fit. Understanding these drivers lets you build a scoring system that predicts performance better than intuition alone.

Patient Access: Beyond the Catchment Area

Patient access is not just about how many people live near the site. It is about how many of them match the protocol’s inclusion and exclusion criteria, are aware of the trial, and are willing to participate. A site in a dense urban area may have a smaller eligible pool than a rural site with a specialized referral network.

To assess patient access systematically, teams should use three layers: (1) demographic incidence data for the disease in the site’s referral region, (2) the site’s own electronic health record query for diagnosis codes and prior treatments, and (3) an estimate of the site’s current patient volume in the relevant therapeutic area. A site that sees 200 eligible patients per year has a very different enrollment potential than one that sees 20.

Site Readiness: Capacity and Culture

Readiness goes beyond having an IRB approval. It means the site has dedicated coordinator time, experienced regulatory staff, and a culture of prompt query resolution. A common framework evaluates readiness across four axes: staffing (dedicated coordinator hours per week), regulatory experience (number of prior trials with similar complexity), technology (ease of EDC and CTMS integration), and startup speed (average days from contract to first patient).

Sites that score high on readiness often enroll 30–50% faster than those that score low, even when patient access is similar. The reason is simple: a ready site can start screening within weeks of activation, while an unprepared site spends the first two months hiring and training.

Protocol Fit: Complexity and Burden

Protocol complexity directly affects enrollment. A protocol with many exclusion criteria, frequent visits, or invasive procedures will enroll slower at any site. The best selection frameworks include a protocol burden score and match it to site experience. Sites that have successfully run similar-complexity trials in the past are more likely to stay on track.

One practical approach is to create a complexity tier (low, medium, high) and only select sites that have demonstrated success in that tier. A site that has only run low-complexity observational studies will struggle with a high-complexity interventional trial requiring biopsies and overnight stays.

Building a Repeatable Selection Process

Moving from intuition to a process means standardizing how you gather and weigh information. The following steps outline a process that many clinical operations teams have adopted, with variations based on therapeutic area and trial phase.

Step 1: Create a Feasibility Scorecard

Start by defining the criteria that matter most for your specific protocol. A generic scorecard might include: patient volume (weight 30%), past enrollment rate in similar trials (25%), coordinator availability (20%), PI experience (15%), and site infrastructure (10%). Adjust weights based on your trial’s needs. For a rare disease trial, patient volume might be 50%; for a device trial, infrastructure might be 30%.

Score each candidate site on a 1–5 scale for each criterion. Multiply by the weight and sum to get a total feasibility score. Use this score to rank sites, but do not treat it as the final answer—it is a starting point for deeper investigation.

Step 2: Conduct Pre-Qualification Calls

A scorecard alone cannot capture coordinator workload or investigator enthusiasm. Schedule a 30-minute call with each high-scoring site to discuss: current trial load, exact coordinator hours available for your study, how they plan to identify patients (EHR query vs. physician referral), and their typical startup timeline. Document responses in a structured template.

During these calls, listen for red flags: vague answers about patient identification, reluctance to share current workload, or unrealistic enrollment promises. One team reported that a site claiming “we can enroll 20 patients in three months” could not name a single referring physician. That site was deprioritized and later failed to enroll anyone.

Step 3: Validate with Site Visits or Virtual Audits

For the top 2–3 candidate sites, conduct a site visit or a detailed virtual audit. Review their regulatory binder from a recent trial, talk to the coordinator and PI separately, and tour the facility if possible. Look for evidence of organized processes: a clean lab, a dedicated study room, and a team that communicates well.

Virtual audits became standard during the pandemic and remain efficient. Use a checklist that covers: staff training records, equipment calibration, IRB submission history, and data management workflows. A site that cannot produce a training log within 48 hours is likely disorganized.

Tools, Economics, and Maintenance Realities

Implementing a structured selection process requires some investment in tools and time, but the return is substantial. Below we compare three common approaches to site selection, along with their costs and trade-offs.

Comparison of Selection Approaches

Most teams find that the scorecard-plus-calls approach offers the best balance for Phase 2 and 3 trials. For pivotal Phase 3 trials or rare disease studies, the full audit is often worth the extra cost because a single site failure can delay the entire program.

Maintenance: Keeping Data Fresh

Site capabilities change. A coordinator leaves, a PI retires, or a site takes on three new trials. Your feasibility data should be refreshed at least every six months for active site lists. Use a simple CRM or spreadsheet to track changes and re-score sites when you start a new protocol. Some teams use quarterly check-in calls with high-performing sites to maintain relationships and stay updated on capacity.

Growth Mechanics: Positioning for Faster Enrollment

Once you have a selection process, you can use it to build a pipeline of pre-qualified sites. This reduces the time between protocol release and site activation from months to weeks.

Building a Site Network

Instead of starting from scratch for each trial, maintain a list of sites that have scored well in the past. When a new protocol comes in, you already have a shortlist. Over time, this network becomes a strategic asset. One CRO reported that after two years of maintaining a pre-qualified site list, their average site activation time dropped by 40%.

The network should include a mix of academic medical centers, large site networks, and independent sites. Diversification protects against capacity crunches—if one site is overloaded, you have alternatives that already meet your baseline criteria.

Using Technology Wisely

Several commercial platforms offer site feasibility data, but they are not a substitute for direct verification. Use them as a starting point, then apply your own scorecard and calls. The platforms can save time on initial filtering, but the final decision should always involve human judgment and site contact.

A common mistake is to rely solely on platform-generated scores. Platforms aggregate historical data that may be outdated or incomplete. Always cross-reference with a live call.

Risks, Pitfalls, and Mitigations

Even with a structured process, pitfalls remain. Here are the most common ones and how to avoid them.

Overweighting Past Performance

A site that enrolled fast in a previous trial may have had a different coordinator, a less complex protocol, or a more motivated patient population. Past performance is a signal, not a guarantee. Mitigation: always combine past performance with current capacity and patient access data.

Ignoring Coordinator Workload

The PI signs the contract, but the coordinator runs the trial. If the coordinator is already managing four studies, your trial will be deprioritized. Mitigation: ask for the coordinator’s current study list and estimated hours per week during the pre-qual call. If they cannot provide it, consider that a red flag.

Skipping the Site Visit for Budget Reasons

Site visits are expensive, but the cost of a failed site is higher. For critical trials, budget for at least one visit per top candidate. For lower-risk trials, a thorough virtual audit can suffice, but do not skip all direct verification.

Failing to Reassess Mid-Trial

Site performance can change after activation. A coordinator leaves, or a competing trial starts recruiting. Build a mid-trial check-in at month three to reassess enrollment projections. If a site is underperforming, trigger a corrective action plan early rather than waiting until the end of the enrollment period.

Mini-FAQ: Common Questions About Site Selection

How many sites should I select for a typical Phase 3 trial? There is no universal number; it depends on the disease prevalence and enrollment target. A common heuristic is to select 1.5 to 2 times the number of sites you think you need, because 20–30% of sites will underperform. Use your feasibility scorecard to identify the top candidates and then add a buffer of two to three backup sites that you can activate quickly if needed.

Should I use a central IRB or local IRB? Central IRBs can speed startup, but some sites require local IRB approval. Factor IRB type into your site readiness score—sites that accept central IRB typically activate 2–4 weeks faster.

What if all my candidate sites score low on patient access? That is a protocol problem, not a site problem. Consider relaxing exclusion criteria or expanding the geographic scope. If the protocol is too restrictive, even the best site will struggle.

How do I handle sites that exaggerate during the feasibility survey? Build verification into your process. Ask for specific patient names (redacted) or EHR query results. If a site claims 50 eligible patients, ask for the diagnosis codes and date ranges they used. Sites that cannot produce evidence are likely inflating numbers.

Is it worth paying for a commercial feasibility database? It can be, if you use it as a screening tool and not a final answer. The best value comes from combining database output with your own scorecard and site calls. Avoid platforms that lock you into a single data source—flexibility is key.

Synthesis: Turning Insight into Action

Site selection is not about finding the perfect site—it is about systematically reducing risk. By adopting a structured process that balances patient access, site readiness, and protocol fit, you can cut enrollment delays, reduce budget overruns, and bring your drug to market faster.

Start small. If you are currently selecting sites based on gut feel, implement a simple scorecard for your next trial. Add pre-qualification calls for the top candidates. Track the results. Over two or three trials, you will build a dataset that lets you refine your weights and improve your predictions. The goal is not perfection; it is steady improvement.

Remember that every trial is different. Adjust your criteria for therapeutic area, phase, and geographic region. What works for a cardiovascular trial may not work for a rare pediatric disease study. Stay flexible, but always use data over intuition.

The real peak performance fix is not a secret tool or a magic algorithm. It is the discipline to gather the right information before you commit, and the willingness to walk away from a site that looks good on paper but fails your structured assessment. That discipline, applied consistently, is what separates fast-enrolling programs from those that limp to the finish line.